1
|
Hsieh MY, Chen G, Chang DC, Chien SY, Chen MK. The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer. Ann Surg Oncol 2018; 25:2091-2097. [PMID: 29721725 DOI: 10.1245/s10434-018-6497-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Indexed: 01/09/2023]
Abstract
BACKGROUND This study evaluated the efficacy of tegafur-uracil for advanced oral cancer. METHODS From January 2008 to December 2013, clinical data from 356 patients with stage III or IV oral squamous cell carcinoma who received curative surgical resection and postoperative concurrent chemoradiotherapy, treated with or without tegafur-uracil, were analyzed from a prospectively designed database. Tegafur-uracil was orally administered to 114 of the 356 patients. Disease-specific survival (DSS), disease-free survival (DFS), and overall survival (OS) rates were studied. RESULTS In our study, the 5-year OS (p = 0.0008), DFS (p = 0.0034), and DSS (p = 0.0029) rates were significantly better in the tegafur-uracil group than in the control group. Distant metastasis occurred in 16.28% of patients in the tegafur-uracil group and 45.28% in the control group (odds ratio 4.3). The distant metastasis rate in the tegafur-uracil group was significantly lower than the control group, indicating that administration of tegafur-uracil after curative surgical treatment and concurrent chemoradiotherapy prevented distant metastasis and improved the OS, DFS, and DSS rate. CONCLUSIONS The result of tegafur-uracil treatment in patients with advanced oral cancer showed significant improvement in the 5-year OS, DFS, and DSS rate, while also showing a decreased distant metastasis rate. Tegafur-uracil treatment is a useful, effective, and well-tolerated anticancer treatment for advanced oral cancer.
Collapse
Affiliation(s)
- Ming-Yu Hsieh
- Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan
| | - Gene Chen
- Southridge School, Surrey, BC, Canada
| | - Dun-Cheng Chang
- Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan
| | - Su-Yu Chien
- Department of Pharmacy, Changhua Christian Hospital, Changhua, Taiwan.,College of Health Sciences, Chang Jung Christian University, Tainan, Taiwan.,Center for General Education, Mingdao University, Changhua, Taiwan
| | - Mu-Kuan Chen
- Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan. .,Changhua Christian Medical Centre, Changhua, Taiwan.
| |
Collapse
|
3
|
Behera M, Owonikoko TK, Kim S, Chen Z, Higgins K, Ramalingam SS, Shin DM, Khuri FR, Beitler JJ, Saba NF. Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. Oral Oncol 2014; 50:888-94. [PMID: 25060589 DOI: 10.1016/j.oraloncology.2014.06.014] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Revised: 06/18/2014] [Accepted: 06/19/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND Platinum compounds remain the most widely utilized systemic agents in combination with radiation for treating SCCHN in the concurrent setting. Despite recent interest in using taxanes in this setting, there is a lack of randomized clinical trials to support this approach. We conducted a systematic review of published clinical trials of taxane-containing versus standard non-taxane-based regimens used in definitive treatment of SCCHN. METHODS Trials published between 1994 and 2012 were identified by an electronic search of public databases (MEDLINE, EMBASE, Cochrane library). All prospective studies were independently identified by two authors for inclusion. Studies were excluded if induction therapy was part of the regimen or if targeted agents were used. Trials using cisplatin- or carboplatin-based regimens and paclitaxel or docetaxel were included. Demographic data, treatment response, locoregional failure free rate (LFFR), progression-free and overall survival (PFS, OS) and toxicities were extracted and analyzed using Comprehensive Meta Analysis software (Version 2.0). Outcome data were pooled and reported as weighted response rate (RR), PFS and OS. RESULTS A total of 790 studies were retrieved and 42 studies with 3120 patients were included: 804 patients were treated with taxanes (80% males, median age 57years) and 2316 with non-taxanes (86% males, median age 56years). Progression free survival was not different between the two groups. Weighted median survival was compared from those studies that reported these data; taxanes=36.7months (N=197) versus non-taxanes=25months (N=503), P<0.001. Toxicity (grade 3 and above) was higher in non-taxane containing trials. CONCLUSIONS The improved overall survival observed supports the choice of taxane-based regimens in the concurrent setting but may also reflect the predominance of single arm multi-agent phase II trials in the taxane arm. Our findings urge the need for better standardization of taxane-based regimens.
Collapse
Affiliation(s)
- Madhusmita Behera
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States
| | - Taofeek K Owonikoko
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States
| | - Sungjin Kim
- Winship Cancer Institute of Emory University, Atlanta, GA, United States; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, United States
| | - Zhengjia Chen
- Winship Cancer Institute of Emory University, Atlanta, GA, United States; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, United States
| | - Kristin Higgins
- Winship Cancer Institute of Emory University, Atlanta, GA, United States; Department of Radiation Oncology, Emory University, Atlanta, GA, United States
| | - Suresh S Ramalingam
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States
| | - Dong M Shin
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States
| | - Fadlo R Khuri
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States
| | - Jonathan J Beitler
- Winship Cancer Institute of Emory University, Atlanta, GA, United States; Department of Radiation Oncology, Emory University, Atlanta, GA, United States
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States; Winship Cancer Institute of Emory University, Atlanta, GA, United States.
| |
Collapse
|